Recurrent Safety
In recurrent GBM,
Patients on Optune Gio experienced fewer systemic AEs than patients on chemotherapy alone1,2
- The most common (≥10%) AEs seen with Optune Gio monotherapy were medical device site reaction and headache3
- The following AEs were considered related to Optune Gio: medical device site reaction, headache, malaise, muscle twitching, fall, and skin ulcer2
- In EF-11, 16% of patients experienced a grade 1/2 medical device site reaction2
- Mild-to-moderate skin irritation, the most common device-related side effect with Optune Gio, was typically manageable, reversible, and did not result in treatment discontinuation2
*Thrombocytopenia from prior chemotherapy, normalized subsequently.
Improved safety vs chemotherapy1
- Significantly fewer of the systemic AEs associated with chemotherapy, including gastrointestinal side effects, hematological side effects, and infections, were observed with Optune Gio
Learn about the pivotal trial study design in recurrent GBM
AEs, adverse events; GBM, glioblastoma.
References: 1. Optune Gio. Instructions for Use. Novocure; 2023. 2. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48(14):2192-2202. 3. Novocure Data on File OPT-109.